JP2014527025A - 吸入用一酸化窒素を用いて血管反応性を決定する方法 - Google Patents
吸入用一酸化窒素を用いて血管反応性を決定する方法 Download PDFInfo
- Publication number
- JP2014527025A JP2014527025A JP2014512110A JP2014512110A JP2014527025A JP 2014527025 A JP2014527025 A JP 2014527025A JP 2014512110 A JP2014512110 A JP 2014512110A JP 2014512110 A JP2014512110 A JP 2014512110A JP 2014527025 A JP2014527025 A JP 2014527025A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- vasoactive agent
- right ventricular
- indicator
- hemodynamics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 75
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims description 260
- 230000002792 vascular Effects 0.000 title description 10
- 230000009257 reactivity Effects 0.000 title description 7
- 229940127293 prostanoid Drugs 0.000 claims abstract description 47
- 150000003814 prostanoids Chemical class 0.000 claims abstract description 47
- 208000008166 Right Ventricular Dysfunction Diseases 0.000 claims abstract description 42
- 230000006814 right ventricular dysfunction Effects 0.000 claims abstract description 42
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims abstract description 40
- 206010013012 Dilatation ventricular Diseases 0.000 claims abstract description 30
- 230000000004 hemodynamic effect Effects 0.000 claims description 119
- 239000002550 vasoactive agent Substances 0.000 claims description 88
- 230000036593 pulmonary vascular resistance Effects 0.000 claims description 85
- 239000003638 chemical reducing agent Substances 0.000 claims description 78
- 230000007423 decrease Effects 0.000 claims description 77
- 238000012544 monitoring process Methods 0.000 claims description 76
- 230000000747 cardiac effect Effects 0.000 claims description 75
- 239000003963 antioxidant agent Substances 0.000 claims description 68
- 235000006708 antioxidants Nutrition 0.000 claims description 68
- 230000003078 antioxidant effect Effects 0.000 claims description 58
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 44
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 claims description 38
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 38
- 239000011149 active material Substances 0.000 claims description 34
- 239000004094 surface-active agent Substances 0.000 claims description 29
- 229940124549 vasodilator Drugs 0.000 claims description 26
- 239000003071 vasodilator agent Substances 0.000 claims description 26
- 230000004872 arterial blood pressure Effects 0.000 claims description 24
- 210000001147 pulmonary artery Anatomy 0.000 claims description 24
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 21
- 235000010323 ascorbic acid Nutrition 0.000 claims description 20
- 239000011668 ascorbic acid Substances 0.000 claims description 20
- 229960005070 ascorbic acid Drugs 0.000 claims description 20
- 230000001154 acute effect Effects 0.000 claims description 17
- 230000008859 change Effects 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000741 silica gel Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- 229940087168 alpha tocopherol Drugs 0.000 claims description 11
- 235000010382 gamma-tocopherol Nutrition 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 229960000984 tocofersolan Drugs 0.000 claims description 11
- 235000004835 α-tocopherol Nutrition 0.000 claims description 11
- 239000002076 α-tocopherol Substances 0.000 claims description 11
- 239000002478 γ-tocopherol Substances 0.000 claims description 11
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000002596 correlated effect Effects 0.000 claims description 5
- 210000005241 right ventricle Anatomy 0.000 description 43
- 238000002560 therapeutic procedure Methods 0.000 description 43
- 238000012360 testing method Methods 0.000 description 38
- 229960001123 epoprostenol Drugs 0.000 description 35
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 35
- 230000002685 pulmonary effect Effects 0.000 description 23
- 239000007864 aqueous solution Substances 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 20
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 20
- 230000007704 transition Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 14
- -1 trepostinil Chemical compound 0.000 description 14
- 210000004204 blood vessel Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000007789 gas Substances 0.000 description 12
- 108010024636 Glutathione Proteins 0.000 description 10
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 10
- 229960003180 glutathione Drugs 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 150000003573 thiols Chemical class 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000012552 review Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 150000003180 prostaglandins Chemical class 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 7
- 238000007726 management method Methods 0.000 description 7
- 239000012047 saturated solution Substances 0.000 description 7
- 230000024883 vasodilation Effects 0.000 description 7
- 238000010606 normalization Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 238000002664 inhalation therapy Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 238000001135 Friedman test Methods 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 238000012313 Kruskal-Wallis test Methods 0.000 description 4
- 238000000585 Mann–Whitney U test Methods 0.000 description 4
- 238000001347 McNemar's test Methods 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 241000387514 Waldo Species 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 229960002890 beraprost Drugs 0.000 description 4
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000000546 chi-square test Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 229960002240 iloprost Drugs 0.000 description 4
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000002815 pulmonary hypertension Diseases 0.000 description 4
- 238000001629 sign test Methods 0.000 description 4
- 238000000528 statistical test Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 150000003595 thromboxanes Chemical class 0.000 description 4
- 230000002227 vasoactive effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000003815 prostacyclins Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000032594 Vascular Remodeling Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011491 glass wool Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000013439 planning Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000011947 six minute walk test Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000032840 Catheter-Related Infections Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010069802 Device related sepsis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 208000006148 High Cardiac Output Diseases 0.000 description 1
- 101000605431 Mus musculus Phospholipid phosphatase 1 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010033433 Pain in jaw Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000008704 pulmonary vasodilation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007725 thermal activation Methods 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/026—Measuring blood flow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Medical Informatics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490929P | 2011-05-27 | 2011-05-27 | |
| US61/490,929 | 2011-05-27 | ||
| PCT/US2012/039401 WO2012166534A1 (en) | 2011-05-27 | 2012-05-24 | Method of determining vasoreactivity using inhaled nitric oxide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017061811A Division JP2017165731A (ja) | 2011-05-27 | 2017-03-27 | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014527025A true JP2014527025A (ja) | 2014-10-09 |
| JP2014527025A5 JP2014527025A5 (https=) | 2015-08-27 |
Family
ID=47259769
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512110A Pending JP2014527025A (ja) | 2011-05-27 | 2012-05-24 | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
| JP2017061811A Ceased JP2017165731A (ja) | 2011-05-27 | 2017-03-27 | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
| JP2019035311A Pending JP2019131556A (ja) | 2011-05-27 | 2019-02-28 | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017061811A Ceased JP2017165731A (ja) | 2011-05-27 | 2017-03-27 | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
| JP2019035311A Pending JP2019131556A (ja) | 2011-05-27 | 2019-02-28 | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11154210B2 (https=) |
| EP (1) | EP2713723B1 (https=) |
| JP (3) | JP2014527025A (https=) |
| AU (1) | AU2012262534B2 (https=) |
| CA (1) | CA2837341C (https=) |
| WO (1) | WO2012166534A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513691A (ja) * | 2016-02-12 | 2019-05-30 | マリンクロット ホスピタル プロダクツ アイピー リミテッド | 吸入用一酸化窒素の左心補助人工心臓への使用とモニタリング |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7618594B2 (en) | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| AU2005277397B2 (en) | 2004-08-18 | 2011-08-25 | VERO Biotech LLC. | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| US7914743B2 (en) | 2008-01-28 | 2011-03-29 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
| JP5878866B2 (ja) | 2009-06-22 | 2016-03-08 | ゲノ エルエルシー | 一酸化窒素治療 |
| JP2014527025A (ja) | 2011-05-27 | 2014-10-09 | ゲノ エルエルシー | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
| EP4024719A1 (en) | 2014-04-15 | 2022-07-06 | CommScope Technologies LLC | Wideband remote unit for distributed antenna system |
| MX2020010523A (es) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Sistemas y metodos para generar oxido nitrico. |
| RU2717525C1 (ru) | 2017-02-27 | 2020-03-23 | Сёрд Поул, Инк. | Системы и способы получения оксида азота |
| US10328228B2 (en) | 2017-02-27 | 2019-06-25 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
| US11672938B1 (en) | 2018-07-18 | 2023-06-13 | Vero Biotech LLC | Start-up protocols for nitric oxide delivery device |
| US20210386944A1 (en) * | 2018-10-12 | 2021-12-16 | Sanotize Research Development Corp. | Gas-evolving compositions and container and delivery systems |
| EP3969416A4 (en) | 2019-05-15 | 2023-11-01 | Third Pole, Inc. | SYSTEMS AND DEVICES FOR GENERATING NITROGEN OXIDE |
| JP2022533628A (ja) | 2019-05-15 | 2022-07-25 | サード ポール，インコーポレイテッド | 一酸化窒素生成用電極 |
| EP3969016A4 (en) | 2019-05-15 | 2023-08-16 | Third Pole, Inc. | ARCHITECTURES FOR THE PRODUCTION OF NITROUS OXIDE |
| US11691879B2 (en) | 2020-01-11 | 2023-07-04 | Third Pole, Inc. | Systems and methods for nitric oxide generation with humidity control |
| US20210395905A1 (en) | 2020-06-18 | 2021-12-23 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
| WO2022082072A1 (en) | 2020-10-16 | 2022-04-21 | Third Pole, Inc. | Nitric oxide generation process controls |
| US11975139B2 (en) | 2021-09-23 | 2024-05-07 | Third Pole, Inc. | Systems and methods for delivering nitric oxide |
| US12569628B2 (en) | 2022-04-14 | 2026-03-10 | Third Pole, Inc. | Delivery of medicinal gas in a liquid medium |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008523090A (ja) * | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
| JP2011010865A (ja) * | 2009-06-30 | 2011-01-20 | Ikaria Holdings Inc | 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法 |
| WO2011063335A1 (en) * | 2009-11-20 | 2011-05-26 | Geno Llc | Nitric oxide delivery system |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6758214B2 (en) | 2000-01-28 | 2004-07-06 | Cyterra Corporation | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
| US7040313B2 (en) | 2001-09-05 | 2006-05-09 | Cyterra Corporation | Method and apparatus for nitric oxide generation |
| AU2005277397B2 (en) | 2004-08-18 | 2011-08-25 | VERO Biotech LLC. | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| US7618594B2 (en) | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| WO2007087575A2 (en) * | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
| AU2008232413B2 (en) | 2007-03-23 | 2013-09-19 | VERO Biotech LLC. | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| US7914743B2 (en) | 2008-01-28 | 2011-03-29 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| EP2306814B1 (en) | 2008-07-24 | 2013-11-27 | Geno LLC | Methods for diagnosing and treating a heart condition in a patient |
| US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
| US10780241B2 (en) | 2008-08-21 | 2020-09-22 | Vero Biotech LLC | Devices and methods for minimizing and treating high-altitude sickness |
| US8701657B2 (en) | 2008-08-21 | 2014-04-22 | Geno Llc | Systems for generating nitric oxide |
| US10960168B2 (en) | 2008-08-21 | 2021-03-30 | Vero Biotech LLC | Delivery of high concentration nitric oxide |
| EP2362810A4 (en) | 2008-09-22 | 2013-09-11 | Geno Llc | CONVERSION OF NITROGEN DIOXIDE (NO2) TO NITROGEN MONOXIDE (NO) |
| JP5878866B2 (ja) | 2009-06-22 | 2016-03-08 | ゲノ エルエルシー | 一酸化窒素治療 |
| US20120093948A1 (en) * | 2009-11-20 | 2012-04-19 | Fine David H | Nitric Oxide Treatments |
| EP2563435B1 (en) | 2010-04-26 | 2020-06-03 | VERO Biotech LLC | Delivery of ultra pure nitric oxide (no) |
| US8268252B2 (en) | 2010-04-26 | 2012-09-18 | Geno Llc | Nitrosyl special connector |
| USD688352S1 (en) | 2010-04-27 | 2013-08-20 | Geno Llc | Female gas connector |
| USD679366S1 (en) | 2010-04-27 | 2013-04-02 | Geno Llc | Male gas connector |
| AU2011336358B2 (en) * | 2010-12-03 | 2016-09-29 | VERO Biotech LLC. | Nitric oxide treatments |
| US20140051737A1 (en) * | 2011-05-10 | 2014-02-20 | Universite Laval | Methods for the treatment and diagnostic of pulmonary arterial hypertension |
| JP2014527025A (ja) | 2011-05-27 | 2014-10-09 | ゲノ エルエルシー | 吸入用一酸化窒素を用いて血管反応性を決定する方法 |
| CA3211190A1 (en) | 2014-10-20 | 2016-04-28 | Vero Biotech LLC | Nitrogen dioxide storage cassette |
-
2012
- 2012-05-24 JP JP2014512110A patent/JP2014527025A/ja active Pending
- 2012-05-24 WO PCT/US2012/039401 patent/WO2012166534A1/en not_active Ceased
- 2012-05-24 AU AU2012262534A patent/AU2012262534B2/en not_active Ceased
- 2012-05-24 EP EP12793863.7A patent/EP2713723B1/en active Active
- 2012-05-24 CA CA2837341A patent/CA2837341C/en active Active
-
2013
- 2013-01-07 US US13/735,558 patent/US11154210B2/en active Active
-
2017
- 2017-03-27 JP JP2017061811A patent/JP2017165731A/ja not_active Ceased
-
2019
- 2019-02-28 JP JP2019035311A patent/JP2019131556A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008523090A (ja) * | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
| JP2011010865A (ja) * | 2009-06-30 | 2011-01-20 | Ikaria Holdings Inc | 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法 |
| WO2011063335A1 (en) * | 2009-11-20 | 2011-05-26 | Geno Llc | Nitric oxide delivery system |
Non-Patent Citations (2)
| Title |
|---|
| JPN5014007396; Ａｄｖａｎｃｅｓ ｉｎ Ｐｕｌｍｏｎａｒｙ Ｈｙｐｅｒｔｅｎｓｉｏｎ Ｖｏｌ．４，Ｎｏ．３, 2005, ｐ１５-２５ * |
| JPN6016006437; Ｊａｐａｎｅｓｅ Ｃｉｒｃｕｌａｔｉｏｎ Ｊｏｕｒｎａｌ Ｖｏｌ．５９，Ｎｏ．Ｓｕｐｐｌ．Ｉ, 1995, ｐ３９１ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513691A (ja) * | 2016-02-12 | 2019-05-30 | マリンクロット ホスピタル プロダクツ アイピー リミテッド | 吸入用一酸化窒素の左心補助人工心臓への使用とモニタリング |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017165731A (ja) | 2017-09-21 |
| AU2012262534A1 (en) | 2013-12-12 |
| JP2019131556A (ja) | 2019-08-08 |
| EP2713723A4 (en) | 2015-03-25 |
| EP2713723A1 (en) | 2014-04-09 |
| AU2012262534B2 (en) | 2016-06-02 |
| EP2713723B1 (en) | 2018-09-12 |
| CA2837341C (en) | 2021-10-19 |
| CA2837341A1 (en) | 2012-12-06 |
| WO2012166534A1 (en) | 2012-12-06 |
| US20130309328A1 (en) | 2013-11-21 |
| US11154210B2 (en) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019131556A (ja) | 吸入用一酸化窒素を用いて血管反応性を決定する方法 | |
| JP3248533B2 (ja) | 呼気中のｎｏレベルの測定に使用されるシステムおよび異常ｎｏレベルに関連する疾患の診断方法 | |
| Gómez et al. | Effects of nebulized NG‐nitro‐L‐arginine methyl ester in patients with hepatopulmonary syndrome | |
| US10362981B2 (en) | Diagnostic methods and systems based on urine analysis | |
| Bihari et al. | Bolus intravenous 0.9% saline, but not 4% albumin or 5% glucose, causes interstitial pulmonary edema in healthy subjects | |
| Fülesdi et al. | Cerebral vasoreactivity to acetazolamide is not impaired in patients with severe sepsis | |
| Prasad et al. | Increased chemiluminescence of polymorphonuclear leucocytes in dogs with volume overload heart failure | |
| Colle et al. | Hepatopulmonary syndrome and portopulmonary hypertension: what’s new | |
| Casey et al. | Hyperbaric hyperoxia reduces exercising forearm blood flow in humans | |
| Lahzami et al. | Small airways function declines after allogeneic haematopoietic stem cell transplantation | |
| Yu et al. | Intradialytic systolic blood pressure variation can predict long-term mortality in patients on maintenance hemodialysis | |
| JP2009516534A5 (https=) | ||
| Valenzuela et al. | Cardiac function in critically ill patients with severe COVID: A prospective cross-sectional study in mechanically ventilated patients | |
| Delaney et al. | Current standard of care for septic shock | |
| Bulte et al. | Myocardial blood flow under general anaesthesia with sevoflurane in type 2 diabetic patients: a pilot study | |
| Heyman et al. | Intrarenal nitric oxide monitoring with a Clark-type electrode: potential pitfalls | |
| RU2365336C1 (ru) | Способ оценки сосудистой мозговой реактивности | |
| Cruz Jr et al. | Effects of intra-aortic balloon occlusion on intestinal perfusion, oxygen metabolism and gastric mucosal PCO2 during experimental hemorrhagic shock | |
| Lehtipalo et al. | Effects of positive end‐expiratory pressure on intestinal circulation during graded mesenteric artery occlusion | |
| Pochron et al. | PS1522 CENTRAL PHYSIOLOGIC MECHANISMS WHICH AUGMENT OXYGEN RELEASE (BOHR EFFECT AND 2, 3‐DPG BINDING) ARE PRESERVED IN THE PRESENCE OF VOXELOTOR AT THE THERAPEUTIC TARGET OF 30% HB MODIFICATION | |
| RU2319961C1 (ru) | Способ прогнозирования течения туберкулеза легких | |
| Evans | Molecular evidence for blood-brain barrier disruption in the absence of structural tissue damage during acute exposure to inspiratory hypoxia | |
| Auzinger | Basic concepts in the management of Acute Liver Failure | |
| JP2015102414A (ja) | ヘリコバクター・ピロリの検出方法及び検出器具 | |
| US20050196868A1 (en) | Use of free hemoglobin and its surrogate markers to detect and monitor pulmonary hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150521 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150521 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150701 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160223 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160519 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160823 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161129 |